Immunovant’s Confidence In Graves’ Disease Builds

 
• By Jessica Merrill

The Roivant-owned company announced positive Phase II data for batoclimab in Graves’ disease and plans to advance next-generation IMVT-1402 into Phase III.

Immunovant announced positive data in Graves' disease • Source: Shutterstock

More from Clinical Trials

More from R&D